95.5% of patients with relapsed or
refractory marginal zone lymphoma (MZL) treated with lisocabtagene
maraleucel (liso-cel) achieved a response, with 62.1% achieving
complete response and 88.6% maintaining a response at 24
months
New data show liso-cel demonstrated high
rates of durable responses and a consistent safety profile in a
fifth cancer type, the most of any CD19-directed CAR T cell
therapy
Additional liso-cel data at ICML 2025
further reinforce BMS’ commitment to unlocking the full potential
of this therapy for patients
Bristol Myers Squibb (NYSE: BMY) today announced the first
disclosure of the primary analysis results of the marginal zone
lymphoma (MZL) cohort of TRANSCEND FL, an open-label, global,
multicenter, Phase 2, single-arm study evaluating Breyanzi
(lisocabtagene maraleucel; liso-cel) in patients with relapsed or
refractory disease. The new data will be presented at the 2025
International Conference on Malignant Lymphoma (ICML) in an oral
presentation on June 19, building on positive topline results
announced in February.
“Liso-cel achieved high, lasting response rates in patients with
relapsed or refractory marginal zone lymphoma, underscoring the
potential of this one-time therapy to significantly improve patient
outcomes,” said M. Lia Palomba, M.D., TRANSCEND FL study
investigator and lymphoma and cell therapy specialist, Memorial
Sloan Kettering Cancer Center. “Currently, the median survival for
patients with marginal zone lymphoma with multiple relapses is 3 to
5 years, signifying an urgent need for transformative therapies
that can effectively address this hard-to-treat disease.”
The MZL cohort of TRANSCEND FL enrolled adults with relapsed or
refractory disease treated with liso-cel in the third-line plus
setting. Patients received treatment with liso-cel at a target dose
of 100 x 106 CAR-positive viable T cells.
In efficacy-evaluable patients with relapsed or refractory MZL
treated with liso-cel (n=66), liso-cel demonstrated clinically
meaningful benefit, with high rates of durable responses. The
overall response rate (ORR) was 95.5% (95% CI: 87.3-99.1; one-sided
p<0.0001), with 62.1% of patients achieving a complete response
(CR) (95% CI: 49.3-73.8; one-sided p<0.0001) by independent
review committee per CT. With a median follow-up of 21.6, 23.8, and
24.5 months, respectively, the 24-month rates were 88.6% for
duration of response, 85.7% for progression-free survival, and
90.4% for overall survival.
Liso-cel exhibited a consistent safety profile, with low rates
of severe cytokine release syndrome (CRS) and neurologic events
(NE) with no new safety signals observed. Any grade CRS occurred in
76% of patients, with Grade 3 CRS occurring in 4% of patients and
no Grade 4/5 CRS reported. Any grade NEs were reported in 33% of
patients, with Grade 3 NEs occurring in 4% of patients and no Grade
4/5 NEs reported. The study will continue to evaluate ORR and
safety in patients through the final analysis.
“MZL is an indolent disease but remains an area of high unmet
need for patients who are relapsing and reaching later lines of
treatment,” said Rosanna Ricafort, vice president, Senior Global
Program Lead for Hematology and Cell Therapy, Bristol Myers Squibb.
“We are proud to present for the first time the primary analysis
data from the MZL cohort of TRANSCEND FL, underscoring our
commitment to unlock the full potential of cell therapy to help
patients living with relapsed or refractory lymphomas. As
highlighted by the data at ICML, Breyanzi continues to cover the
broadest patient eligibility of any CAR T for B-cell malignancies
and demonstrates a safety profile consistent with clinical trials
and in the real-world setting for approved indications.”
Additional key Bristol Myers Squibb data presentations on
liso-cel at ICML 2025 include:
Title: Lisocabtagene maraleucel in
R/R FL (TRANSCEND FL): impact of prior lines of therapy,
bendamustine exposure, and disease progression ≤24 months of
initial systemic therapy Oral presentation: Thursday,
June 19 Key findings: Results support the sustained clinical
benefit and safety profile of liso-cel for patients with R/R
regardless of POD24 status and prior bendamustine exposure with a
trend for better outcomes in earlier lines of therapy.
Title: Matching-adjusted indirect
comparison of lisocabtagene maraleucel versus epcoritamab in
patients with third-line or later relapsed or refractory follicular
lymphoma Poster session: Thursday, June 19 Key
findings: The data support liso-cel as an effective treatment
for patients with third-line plus R/R FL, potentially offering
improved efficacy over epcoritamab in this setting.
Title: Comparative outcomes of
lisocabtagene maraleucel (liso-cel) versus an external control arm
(ECA) in third-line or later (3L+) R/R follicular lymphoma (FL)
Poster session: Friday, June 20 Key findings:
Liso-cel appeared to show better efficacy than SOC therapies in
patients with third-line plus R/R FL, further supporting it as an
important treatment option to improve patient outcomes in this
setting.
Title: Optimizing post–chimeric antigen
receptor T cell monitoring: evidence across lisocabtagene
maraleucel pivotal clinical trials and real-world experience
(recently presented at the American Society of Clinical Oncology
meeting) Poster session: Friday, June 20 Key
findings: Results showed that most cytokine release syndrome
and immune effector cell-associated neurotoxicity syndrome events
in patients treated with liso-cel occurred less than 2 weeks after
infusion and were not severe, providing insight into the onset of
these events across clinical trials and in the real-world
setting.
Bristol Myers Squibb thanks the patients and investigators
involved in the clinical trials.
About TRANSCEND FL
TRANSCEND FL (NCT04245839) is an open-label, global,
multicenter, Phase 2, single-arm study to determine the efficacy
and safety of Breyanzi in patients with relapsed or refractory
indolent B-cell non-Hodgkin lymphoma, including follicular lymphoma
and marginal zone lymphoma. The primary outcome measure is overall
response rate. Secondary outcome measures include complete response
rate, duration of response, and progression-free survival.
About MZL
Marginal zone lymphoma (MZL) is the third most common lymphoma,
accounting for about 7% of all non-Hodgkin lymphoma cases. Most
patients with MZL are at a median age of 67 years when they are
diagnosed. MZL develops when white blood cells cluster together to
form lumps in a person’s lymph nodes or organs. Initial therapy
often leads to remission, but relapse is common, sometimes
occurring several times over many years. A small portion of MZL
cases transform into diffuse large-B-cell lymphoma, a more
aggressive lymphoma.
About Breyanzi
Breyanzi is a CD19-directed CAR T cell therapy with a 4-1BB
costimulatory domain, which enhances the expansion and persistence
of the CAR T cells. Breyanzi is made from a patient’s own T cells,
which are collected and genetically reengineered to become CAR T
cells that are then delivered via infusion as a one-time
treatment.
Breyanzi is approved in the U.S. for the treatment of relapsed
or refractory large B-cell lymphoma (LBCL) after at least one prior
line of therapy, has received accelerated approval for the
treatment of relapsed or refractory chronic lymphocytic leukemia or
small lymphocytic lymphoma after at least two prior lines of
therapy and relapsed or refractory follicular lymphoma (FL) in the
third-line plus setting, and is approved for the treatment of
relapsed or refractory mantle cell lymphoma in the third-line plus
setting. Breyanzi is also approved in Japan, the European Union
(EU), Switzerland, the United Kingdom and Canada for the treatment
of relapsed or refractory LBCL after at least one prior line of
therapy; in Japan for the treatment of patients with relapsed or
refractory high-risk FL after one prior line of systemic therapy
and in patients with relapsed or refractory FL after two or more
lines of systemic therapy; and in the EU for the treatment of
relapsed or refractory FL after two or more lines of systemic
therapy.
Bristol Myers Squibb’s clinical development program for Breyanzi
includes clinical studies in several types of lymphoma. For more
information, visit clinicaltrials.gov.
U.S. FDA-Approved
Indications
BREYANZI is a CD19-directed genetically modified autologous T
cell immunotherapy indicated for the treatment of:
- adult patients with large B-cell lymphoma (LBCL), including
diffuse large B-cell lymphoma (DLBCL) not otherwise specified
(including DLBCL arising from indolent lymphoma), high-grade B cell
lymphoma, primary mediastinal large B-cell lymphoma, and follicular
lymphoma grade 3B, who have:
- refractory disease to first-line chemoimmunotherapy or relapse
within 12 months of first-line chemoimmunotherapy; or
- refractory disease to first-line chemoimmunotherapy or relapse
after first-line chemoimmunotherapy and are not eligible for
hematopoietic stem cell transplantation (HSCT) due to comorbidities
or age; or
- relapsed or refractory disease after two or more lines of
systemic therapy.
Limitations of Use: BREYANZI is not
indicated for the treatment of patients with primary central
nervous system lymphoma.
- adult patients with relapsed or refractory chronic lymphocytic
leukemia (CLL) or small lymphocytic lymphoma (SLL) who have
received at least 2 prior lines of therapy, including a Bruton
tyrosine kinase (BTK) inhibitor and a B-cell lymphoma 2 (BCL-2)
inhibitor. This indication is approved under accelerated approval
based on response rate and duration of response. Continued approval
for this indication may be contingent upon verification and
description of clinical benefit in confirmatory trial(s).
- adult patients with relapsed or refractory follicular lymphoma
(FL) who have received 2 or more prior lines of systemic therapy.
This indication is approved under accelerated approval based on
response rate and duration of response. Continued approval for this
indication may be contingent upon verification and description of
clinical benefit in confirmatory trial(s).
- adult patients with relapsed or refractory mantle cell lymphoma
(MCL) who have received at least 2 prior lines of systemic therapy,
including a Bruton tyrosine kinase (BTK) inhibitor.
U.S. Important Safety
Information
WARNING: CYTOKINE RELEASE SYNDROME, NEUROLOGIC TOXICITIES,
AND SECONDARY HEMATOLOGICAL MALIGNANCIES
- Cytokine Release Syndrome (CRS), including fatal or
life-threatening reactions, occurred in patients receiving
BREYANZI. Do not administer BREYANZI to patients with active
infection or inflammatory disorders. Treat severe or
life-threatening CRS with tocilizumab with or without
corticosteroids.
- Neurologic toxicities, including fatal or life-threatening
reactions, occurred in patients receiving BREYANZI, including
concurrently with CRS, after CRS resolution, or in the absence of
CRS. Monitor for neurologic events after treatment with BREYANZI.
Provide supportive care and/or corticosteroids as needed.
- T cell malignancies have occurred following treatment of
hematologic malignancies with BCMA- and CD19-directed genetically
modified autologous T cell immunotherapies, including
BREYANZI.
- BREYANZI is available only through a restricted program
under a Risk Evaluation and Mitigation Strategy (REMS) called the
BREYANZI REMS.
Cytokine Release Syndrome
Cytokine release syndrome (CRS), including fatal or
life-threatening reactions, occurred following treatment with
BREYANZI. In clinical trials of BREYANZI, which enrolled a total of
702 patients with non-Hodgkin lymphoma (NHL), CRS occurred in 54%
of patients, including ≥ Grade 3 CRS in 3.2% of patients. The
median time to onset was 5 days (range: 1 to 63 days). CRS resolved
in 98% of patients with a median duration of 5 days (range: 1 to 37
days). One patient had fatal CRS and 5 patients had ongoing CRS at
the time of death. The most common manifestations of CRS (≥10%)
were fever, hypotension, tachycardia, chills, hypoxia, and
headache.
Serious events that may be associated with CRS include cardiac
arrhythmias (including atrial fibrillation and ventricular
tachycardia), cardiac arrest, cardiac failure, diffuse alveolar
damage, renal insufficiency, capillary leak syndrome, hypotension,
hypoxia, and hemophagocytic lymphohistiocytosis/macrophage
activation syndrome (HLH/MAS).
Ensure that 2 doses of tocilizumab are available prior to
infusion of BREYANZI.
Neurologic Toxicities
Neurologic toxicities that were fatal or life-threatening,
including immune effector cell-associated neurotoxicity syndrome
(ICANS), occurred following treatment with BREYANZI. Serious events
including cerebral edema and seizures occurred with BREYANZI. Fatal
and serious cases of leukoencephalopathy, some attributable to
fludarabine, also occurred.
In clinical trials of BREYANZI, CAR T cell-associated neurologic
toxicities occurred in 31% of patients, including ≥ Grade 3 cases
in 10% of patients. The median time to onset of neurotoxicity was 8
days (range: 1 to 63 days). Neurologic toxicities resolved in 88%
of patients with a median duration of 7 days (range: 1 to 119
days). Of patients developing neurotoxicity, 82% also developed
CRS.
The most common neurologic toxicities (≥5%) included
encephalopathy, tremor, aphasia, headache, dizziness, and
delirium.
CRS and Neurologic Toxicities Monitoring
Monitor patients daily for at least 7 days following BREYANZI
infusion at a REMS-certified healthcare facility for signs and
symptoms of CRS and neurologic toxicities and assess for other
causes of neurological symptoms. Monitor patients for signs and
symptoms of CRS and neurologic toxicities for at least 4 weeks
after infusion and treat promptly. At the first sign of CRS,
institute treatment with supportive care, tocilizumab, or
tocilizumab and corticosteroids as indicated. Manage neurologic
toxicity with supportive care and/or corticosteroid as needed.
Counsel patients to seek immediate medical attention should signs
or symptoms of CRS or neurologic toxicity occur at any time.
BREYANZI REMS
Because of the risk of CRS and neurologic toxicities, BREYANZI
is available only through a restricted program under a Risk
Evaluation and Mitigation Strategy (REMS) called the BREYANZI REMS.
The required components of the BREYANZI REMS are:
- Healthcare facilities that dispense and administer BREYANZI
must be enrolled and comply with the REMS requirements.
- Certified healthcare facilities must have on-site, immediate
access to tocilizumab.
- Ensure that a minimum of 2 doses of tocilizumab are available
for each patient for infusion within 2 hours after BREYANZI
infusion, if needed for treatment of CRS.
Further information is available at www.BreyanziREMS.com, or
contact Bristol Myers Squibb at 1-866-340-7332.
Hypersensitivity Reactions
Allergic reactions may occur with the infusion of BREYANZI.
Serious hypersensitivity reactions, including anaphylaxis, may be
due to dimethyl sulfoxide (DMSO).
Serious Infections
Severe infections, including life-threatening or fatal
infections, have occurred in patients after BREYANZI infusion. In
clinical trials of BREYANZI, infections of any grade occurred in
34% of patients, with Grade 3 or higher infections occurring in 12%
of all patients. Grade 3 or higher infections with an unspecified
pathogen occurred in 7%, bacterial infections in 3.7%, viral
infections in 2%, and fungal infections in 0.7% of patients. One
patient who received 4 prior lines of therapy developed a fatal
case of John Cunningham (JC) virus progressive multifocal
leukoencephalopathy 4 months after treatment with BREYANZI. One
patient who received 3 prior lines of therapy developed a fatal
case of cryptococcal meningoencephalitis 35 days after treatment
with BREYANZI.
Febrile neutropenia developed after BREYANZI infusion in 8% of
patients. Febrile neutropenia may be concurrent with CRS. In the
event of febrile neutropenia, evaluate for infection and manage
with broad-spectrum antibiotics, fluids, and other supportive care
as medically indicated.
Monitor patients for signs and symptoms of infection before and
after BREYANZI administration and treat appropriately. Administer
prophylactic antimicrobials according to standard institutional
guidelines. Avoid administration of BREYANZI in patients with
clinically significant, active systemic infections.
Viral reactivation: Hepatitis B virus (HBV) reactivation, in
some cases resulting in fulminant hepatitis, hepatic failure, and
death, can occur in patients treated with drugs directed against B
cells. In clinical trials of BREYANZI, 35 of 38 patients with a
prior history of HBV were treated with concurrent antiviral
suppressive therapy.
Perform screening for HBV, HCV, and HIV in accordance with
clinical guidelines before collection of cells for manufacturing.
In patients with prior history of HBV, consider concurrent
antiviral suppressive therapy to prevent HBV reactivation per
standard guidelines.
Prolonged Cytopenias
Patients may exhibit cytopenias not resolved for several weeks
following lymphodepleting chemotherapy and BREYANZI infusion. In
clinical trials of BREYANZI, Grade 3 or higher cytopenias persisted
at Day 29 following BREYANZI infusion in 35% of patients, and
included thrombocytopenia in 25%, neutropenia in 22%, and anemia in
6% of patients. Monitor complete blood counts prior to and after
BREYANZI administration.
Hypogammaglobulinemia
B-cell aplasia and hypogammaglobulinemia can occur in patients
receiving BREYANZI. In clinical trials of BREYANZI,
hypogammaglobulinemia was reported as an adverse reaction in 10% of
patients. Hypogammaglobulinemia, either as an adverse reaction or
laboratory IgG level below 500 mg/dL after infusion, was reported
in 30% of patients. Monitor immunoglobulin levels after treatment
with BREYANZI and manage using infection precautions, antibiotic
prophylaxis, and immunoglobulin replacement as clinically
indicated.
Live vaccines: The safety of immunization with live viral
vaccines during or following BREYANZI treatment has not been
studied. Vaccination with live virus vaccines is not recommended
for at least 6 weeks prior to the start of lymphodepleting
chemotherapy, during BREYANZI treatment, and until immune recovery
following treatment with BREYANZI.
Secondary Malignancies
Patients treated with BREYANZI may develop secondary
malignancies. T cell malignancies have occurred following treatment
of hematologic malignancies with BCMA- and CD19-directed
genetically modified autologous T cell immunotherapies, including
BREYANZI. Mature T cell malignancies, including CAR-positive
tumors, may present as soon as weeks following infusion, and may
include fatal outcomes. Monitor lifelong for secondary
malignancies. In the event that a secondary malignancy occurs,
contact Bristol Myers Squibb at 1-888-805-4555 for reporting and to
obtain instructions on collection of patient samples for
testing.
Effects on Ability to Drive and Use Machines
Due to the potential for neurologic events, including altered
mental status or seizures, patients receiving BREYANZI are at risk
for developing altered or decreased consciousness or impaired
coordination in the 8 weeks following BREYANZI administration.
Advise patients to refrain from driving and engaging in hazardous
occupations or activities, such as operating heavy or potentially
dangerous machinery, for at least 8 weeks.
Immune Effector Cell-Associated Hemophagocytic
Lymphohistiocytosis-Like Syndrome (IEC-HS)
Immune Effector Cell-Associated Hemophagocytic
Lymphohistiocytosis-Like Syndrome (IEC-HS), including fatal or
life-threatening reactions, occurred following treatment with
BREYANZI. Three of 89 (3%) safety evaluable patients with R/R
CLL/SLL developed IEC-HS. Time to onset of IEC-HS ranged from 7 to
18 days. Two of the 3 patients developed IEC-HS in the setting of
ongoing CRS and 1 in the setting of ongoing neurotoxicity. IEC-HS
was fatal in 2 of 3 patients. One patient had fatal IEC-HS and one
had ongoing IEC-HS at time of death. IEC-HS is a life-threatening
condition with a high mortality rate if not recognized and treated
early. Treatment of IEC-HS should be administered per current
practice guidelines.
Adverse Reactions
The most common adverse reaction(s) (incidence ≥30%) in:
- LBCL are fever, cytokine release syndrome, fatigue,
musculoskeletal pain, and nausea. The most common Grade 3-4
laboratory abnormalities include lymphocyte count decrease,
neutrophil count decrease, platelet count decrease, and hemoglobin
decrease.
- CLL/SLL are cytokine release syndrome, encephalopathy, fatigue,
musculoskeletal pain, nausea, edema, and diarrhea. The most common
Grade 3-4 laboratory abnormalities include neutrophil count
decrease, white blood cell decrease, hemoglobin decrease, platelet
count decrease, and lymphocyte count decrease.
- FL is cytokine release syndrome. The most common Grade 3-4
laboratory abnormalities include lymphocyte count decrease,
neutrophil count decrease, and white blood cell decrease.
- MCL are cytokine release syndrome, fatigue, musculoskeletal
pain, and encephalopathy. The most common Grade 3-4 laboratory
abnormalities include neutrophil count decrease, white blood cell
decrease, and platelet count decrease.
Please see full Prescribing Information, including
Boxed WARNINGS and Medication Guide.
Bristol Myers Squibb: Unlocking the
Full Potential of Cell Therapy
A pioneer in harnessing the immune system to fight cancer and an
established leader in cell therapy, Bristol Myers Squibb is
uniquely positioned to unlock the full potential of this technology
across blood cancers and within new frontiers, including autoimmune
disease.
Bristol Myers Squibb is currently the only company with two
approved CAR T cell therapies with two distinct targets, available
in major markets around the world. Our bold vision for the future
is one in which hundreds of thousands of patients can be treated
with cell therapy’s transformational potential.
The building blocks to realize this ambition—a promising and
differentiated pipeline, extensive translational and clinical data
sets, a deep bench of talent, and robust manufacturing
capabilities— are in our cells. We are laser-focused on advancing
the field of cell therapy toward a true revolution for patients.
Learn more about the science behind cell therapy and ongoing
progress at Bristol Myers Squibb here.
About Bristol Myers
Squibb
Bristol Myers Squibb is a global biopharmaceutical company whose
mission is to discover, develop and deliver innovative medicines
that help patients prevail over serious diseases. For more
information about Bristol Myers Squibb, visit us at BMS.com or
follow us on LinkedIn, X, YouTube, Facebook and Instagram.
Cautionary Statement Regarding
Forward-Looking Statements
This press release contains “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act of 1995
regarding, among other things, the research, development and
commercialization of pharmaceutical products. All statements that
are not statements of historical facts are, or may be deemed to be,
forward-looking statements. Such forward-looking statements are
based on current expectations and projections about our future
financial results, goals, plans and objectives and involve inherent
risks, assumptions and uncertainties, including internal or
external factors that could delay, divert or change any of them in
the next several years, that are difficult to predict, may be
beyond our control and could cause our future financial results,
goals, plans and objectives to differ materially from those
expressed in, or implied by, the statements. These risks,
assumptions, uncertainties and other factors include, whether
Breyanzi (lisocabtagene maraleucel) for the additional indication
described in this release will be commercially successful, any
marketing approvals, if granted, may have significant limitations
on their use, and that continued approval of Breyanzi for such
additional indication described in this release may be contingent
upon verification and description of clinical benefit in
confirmatory trials. No forward-looking statement can be
guaranteed. Forward-looking statements in this press release should
be evaluated together with the many risks and uncertainties that
affect Bristol Myers Squibb’s business and market, particularly
those identified in the cautionary statement and risk factors
discussion in Bristol Myers Squibb’s Annual Report on Form 10-K for
the year ended December 31, 2024, as updated by our subsequent
Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and
other filings with the Securities and Exchange Commission. The
forward-looking statements included in this document are made only
as of the date of this document and except as otherwise required by
applicable law, Bristol Myers Squibb undertakes no obligation to
publicly update or revise any forward-looking statement, whether as
a result of new information, future events, changed circumstances
or otherwise.
corporatefinancial-news
View source
version on businesswire.com: https://www.businesswire.com/news/home/20250613870408/en/
Bristol Myers Squibb Media Inquiries:
media@bms.com Investors: investor.relations@bms.com
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Jun 2025 to Jul 2025
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Jul 2024 to Jul 2025
